{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:06:01Z","timestamp":1789383961136,"version":"build-2803163510"},"reference-count":108,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40487-026-00445-8","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T18:35:40Z","timestamp":1781202940000},"page":"869-893","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Beyond the BCG Paradox: Biological Rationale and Clinical Evidence for Combining Intravesical BCG with Immune Checkpoint Inhibitors in High-Risk Non-muscle-Invasive Bladder Cancer"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1529-982X","authenticated-orcid":false,"given":"Michele","family":"Musone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biagio","family":"Barone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Chianese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Conforti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Madonna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvestro","family":"Imperatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Dinacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Balsamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lucarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Falabella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo Francesco","family":"Caputo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Luigi","family":"Pastore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Fuschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Fabiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste","family":"Manfredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Maria","family":"Busetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"Santarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Del Giudice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4315-7660","authenticated-orcid":false,"given":"Felice","family":"Crocetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"issue":"3","key":"445_CR1","doi-asserted-by":"publisher","first-page":"586","DOI":"10.3390\/diagnostics12030586","volume":"12","author":"M Ferro","year":"2022","unstructured":"Ferro M, T\u0103taru OS, Musi G, Lucarelli G, Abu Farhan AR, Cantiello F, et\u00a0al. Modified Glasgow prognostic score as a predictor of recurrence in patients with high grade non-muscle invasive bladder cancer undergoing intravesical bacillus Calmette-Guerin Immunotherapy. Diagnostics (Basel, Switzerland). 2022;12(3):586. https:\/\/doi.org\/10.3390\/diagnostics12030586.","journal-title":"Diagnostics (Basel, Switzerland)"},{"issue":"2","key":"445_CR2","doi-asserted-by":"publisher","first-page":"180","DOI":"10.23736\/S2724-6051.22.04953-9","volume":"75","author":"R Contieri","year":"2023","unstructured":"Contieri R, Hurle R, Paciotti M, Casale P, Saita A, Porpiglia F, et\u00a0al. Accuracy of the European Association of Urology (EAU) NMIBC 2021 scoring model in predicting progression in a large cohort of HG T1 patients with NMIBC treated with BCG. Minerva Urol Nefrol. 2023;75(2):180\u20137. https:\/\/doi.org\/10.23736\/S2724-6051.22.04953-9.","journal-title":"Minerva Urol Nefrol"},{"issue":"3","key":"445_CR3","doi-asserted-by":"publisher","first-page":"512","DOI":"10.3390\/jpm13030512","volume":"13","author":"B Barone","year":"2023","unstructured":"Barone B, Finati M, Cinelli F, Fanelli A, Del Giudice F, De Berardinis E, et\u00a0al. Bladder cancer and risk factors: data from a multi-institutional long-term analysis on cardiovascular disease and cancer incidence. J Pers Med. 2023;13(3):512. https:\/\/doi.org\/10.3390\/jpm13030512.","journal-title":"J Pers Med"},{"issue":"2","key":"445_CR4","doi-asserted-by":"publisher","first-page":"e166","DOI":"10.1016\/j.clgc.2021.12.005","volume":"20","author":"M Ferro","year":"2022","unstructured":"Ferro M, Chiujdea S, Musi G, Lucarelli G, Del Giudice F, Hurle R, et\u00a0al. Impact of age on outcomes of patients with pure carcinoma in situ of the bladder: multi-institutional cohort analysis. Clin Genitourin Cancer. 2022;20(2):e166\u201372. https:\/\/doi.org\/10.1016\/j.clgc.2021.12.005.","journal-title":"Clin Genitourin Cancer"},{"issue":"9","key":"445_CR5","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.3390\/cancers17091477","volume":"17","author":"F Del Giudice","year":"2025","unstructured":"Del Giudice F, Abu-Ghanem Y, Nair R, Mensah E, Kam J, Ibrahim Y, et\u00a0al. Contemporary trends and predictors associated with adverse pathological upstaging among non-metastatic localized clinical T2 Muscle-invasive bladder cancers undergoing radical cystectomy: outcomes from a single tertiary centre in the United Kingdom. Cancers. 2025;17(9):1477. https:\/\/doi.org\/10.3390\/cancers17091477.","journal-title":"Cancers"},{"issue":"19","key":"445_CR6","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.3390\/cancers17193110","volume":"17","author":"F Del Giudice","year":"2025","unstructured":"Del Giudice F, Santarelli V, Spurna K, Ali Kirmani SG, Bhatti NH, Abu-Ghanem Y, et\u00a0al. Contemporary trends and predictors of pT0 in radical cystectomy specimens among non-muscle and muscle-invasive bladder cancer patients: a propensity score-matched analysis from a single tertiary centre in the United Kingdom. Cancers. 2025;17(19):3110. https:\/\/doi.org\/10.3390\/cancers17193110.","journal-title":"Cancers"},{"issue":"7","key":"445_CR7","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.3390\/cancers15071937","volume":"15","author":"F Del Giudice","year":"2023","unstructured":"Del Giudice F, Asero V, Bologna E, Scornajenghi CM, Carino D, Dolci V, et\u00a0al. Efficacy of different bacillus of Calmette-Gu\u00e9rin (BCG) strains on recurrence rates among intermediate\/high-risk non-muscle invasive bladder cancers (NMIBCs): single-arm study systematic review, cumulative and network meta-analysis. Cancers. 2023;15(7):1937. https:\/\/doi.org\/10.3390\/cancers15071937.","journal-title":"Cancers"},{"issue":"21","key":"445_CR8","doi-asserted-by":"publisher","first-page":"5276","DOI":"10.3390\/cancers13215276","volume":"13","author":"M Ferro","year":"2021","unstructured":"Ferro M, Del Giudice F, Carrieri G, Busetto GM, Cormio L, Hurle R, et\u00a0al. The impact of SARS-CoV-2 pandemic on time to primary, secondary resection and adjuvant intravesical therapy in patients with high-risk non-muscle invasive bladder cancer: a retrospective multi-institutional cohort analysis. Cancers. 2021;13(21):5276. https:\/\/doi.org\/10.3390\/cancers13215276.","journal-title":"Cancers"},{"issue":"3","key":"445_CR9","doi-asserted-by":"publisher","first-page":"69.e17","DOI":"10.1016\/j.urolonc.2024.01.001","volume":"42","author":"A Porreca","year":"2024","unstructured":"Porreca A, Di Nicola M, Lucarelli G, Dorin VM, Soria F, Terracciano D, et\u00a0al. Time to progression is the main predictor of survival in patients with high-risk nonmuscle invasive bladder cancer: Results from a machine learning-based analysis of a large multi-institutional database. Urol Oncol. 2024;42(3):69.e17-69.e25. https:\/\/doi.org\/10.1016\/j.urolonc.2024.01.001.","journal-title":"Urol Oncol"},{"key":"445_CR10","doi-asserted-by":"publisher","first-page":"1092969","DOI":"10.3389\/fonc.2023.1092969","volume":"13","author":"X Chen","year":"2023","unstructured":"Chen X, He F, Zhang W, Fu Y, Cao Z. Emerging trends of BCG immunotherapy for bladder cancer in last decade: a bibliometric and visualization analysis. Front Oncol. 2023;13:1092969. https:\/\/doi.org\/10.3389\/fonc.2023.1092969.","journal-title":"Front Oncol"},{"issue":"1","key":"445_CR11","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12967-023-03944-8","volume":"21","author":"J Chen","year":"2023","unstructured":"Chen J, Gao L, Wu X, Fan Y, Liu M, Peng L, et\u00a0al. BCG-induced trained immunity: history, mechanisms and potential applications. J Transl Med. 2023;21(1):106.","journal-title":"J Transl Med"},{"issue":"10","key":"445_CR12","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41585-021-00481-1","volume":"18","author":"N Lobo","year":"2021","unstructured":"Lobo N, Brooks NA, Zlotta AR, Cirillo JD, Boorjian S, Black PC, et\u00a0al. 100 years of Bacillus Calmette\u2013Gu\u00e9rin immunotherapy: from cattle to COVID-19. Nat Rev Urol. 2021;18(10):611\u201322. https:\/\/doi.org\/10.1038\/s41585-021-00481-1.","journal-title":"Nat Rev Urol"},{"issue":"1","key":"445_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0271-0","volume":"5","author":"AM Kamat","year":"2017","unstructured":"Kamat AM, Bellmunt J, Galsky MD, Konety BR, Lamm DL, Langham D, et\u00a0al. Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. J Immunother Cancer. 2017;5(1):68. https:\/\/doi.org\/10.1186\/s40425-017-0271-0.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"445_CR14","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/bju.16293","volume":"133","author":"R Contieri","year":"2024","unstructured":"Contieri R, Tan WS, Grajales V, Hensley PJ, Martini A, Bree K, et\u00a0al. Influence of lamina propria invasion extension on T1 high-grade non-muscle-invasive bladder cancer in patients undergoing BCG or radical cystectomy. BJU Int. 2024;133(6):733\u201341. https:\/\/doi.org\/10.1111\/bju.16293.","journal-title":"BJU Int"},{"issue":"9","key":"445_CR15","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1007\/s00345-021-03653-1","volume":"39","author":"D D\u2019Andrea","year":"2021","unstructured":"D\u2019Andrea D, Soria F, Grotenhuis AJ, Cha EK, Malats N, Di Stasi S, et\u00a0al. Association of patients\u2019 sex with treatment outcomes after intravesical Bacillus Calmette\u2013Gu\u00e9rin immunotherapy for T1G3\/HG bladder cancer. World J Urol. 2021;39(9):3337\u201344. https:\/\/doi.org\/10.1007\/s00345-021-03653-1.","journal-title":"World J Urol"},{"issue":"1","key":"445_CR16","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.euo.2021.11.006","volume":"5","author":"N Lobo","year":"2022","unstructured":"Lobo N, Hensley PJ, Bree KK, Nogueras-Gonzalez GM, Navai N, Dinney CP, et\u00a0al. Updated European Association of Urology (EAU) prognostic factor risk groups overestimate the risk of progression in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette\u2013Gu\u00e9rin. Eur Urol Oncol. 2022;5(1):84\u201391. https:\/\/doi.org\/10.1016\/j.euo.2021.11.006.","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"445_CR17","doi-asserted-by":"publisher","first-page":"216","DOI":"10.6004\/jnccn.2024.0024","volume":"22","author":"TW Flaig","year":"2024","unstructured":"Flaig TW, Spiess PE, Abern M, et\u00a0al. NCCN Guidelines\u00ae Insights: Bladder Cancer, Version 3.2024. J Natl Compr Canc Netw. 2024;22(4):216\u201325. https:\/\/doi.org\/10.6004\/jnccn.2024.0024. (Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Bladder Cancer V.1.2025. \u00a9 National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed March 10, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org).","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"445_CR18","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.euo.2024.10.012","volume":"8","author":"D D\u2019Andrea","year":"2025","unstructured":"D\u2019Andrea D, Mostafid H, Gontero P, Shariat S, Kamat A, Masson-Lecomte A, et\u00a0al. Unmet need in non-muscle-invasive bladder cancer failing Bacillus Calmette\u2013Gu\u00e9rin therapy: a systematic review and cost-effectiveness analyses from the International Bladder Cancer Group. Eur Urol Oncol. 2025;8(1):216\u201329. https:\/\/doi.org\/10.1016\/j.euo.2024.10.012.","journal-title":"Eur Urol Oncol"},{"key":"445_CR19","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1100\/tsw.2006.404","volume":"6","author":"RJ Sylvester","year":"2006","unstructured":"Sylvester RJ. Natural history, recurrence, and progression in superficial bladder cancer. ScientificWorldJournal. 2006;6:2617\u201325. https:\/\/doi.org\/10.1100\/tsw.2006.404.","journal-title":"ScientificWorldJournal"},{"issue":"4","key":"445_CR20","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.euf.2018.08.019","volume":"4","author":"WB Tabayoyong","year":"2021","unstructured":"Tabayoyong WB, Kamat AM, O\u2019Donnell MA, McKiernan JM, Ray-Zack MD, Palou J, et\u00a0al. Systematic review on the utilization of maintenance intravesical chemotherapy in the management of non-muscle-invasive bladder cancer. Eur Urol Focus. 2021;4(4):512\u201321. https:\/\/doi.org\/10.1016\/j.euf.2018.08.019.","journal-title":"Eur Urol Focus"},{"issue":"1","key":"445_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-5134-7","volume":"18","author":"M Racioppi","year":"2018","unstructured":"Racioppi M, Di Gianfrancesco L, Ragonese M, Palermo G, Sacco E, Bassi PF. ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk \u201cBCG failure\u201d non muscle invasive bladder cancer: 3\u2009years follow-up outcomes. BMC Cancer. 2018;18(1):1224. https:\/\/doi.org\/10.1186\/s12885-018-5134-7.","journal-title":"BMC Cancer"},{"key":"445_CR22","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2147\/RRU.S63447","volume":"7","author":"O Fuge","year":"2015","unstructured":"Fuge O, Vasdev N, Allchorne P, Green JS. Immunotherapy for bladder cancer. Res Rep Urol. 2015;7:65\u201379. https:\/\/doi.org\/10.2147\/RRU.S63447.","journal-title":"Res Rep Urol"},{"issue":"4","key":"445_CR23","doi-asserted-by":"publisher","first-page":"977","DOI":"10.4161\/hv.27621","volume":"10","author":"MF Chevalier","year":"2014","unstructured":"Chevalier MF, Nardelli-Haefliger D, Domingos-Pereira S, Jichlinski P, Derr\u00e9 L. Immunotherapeutic strategies for bladder cancer. Hum Vaccin Immunother. 2014;10(4):977\u201381. https:\/\/doi.org\/10.4161\/hv.27621.","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"445_CR24","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3892\/mmr.2020.11090","volume":"22","author":"QL Tan","year":"2020","unstructured":"Tan QL, Zhou CY, Cheng L, Luo M, Liu CP, Xu WX, et\u00a0al. Immunotherapy of Bacillus Calmette-Gu\u00e9rin by targeting macrophages against bladder cancer in a NOD\/scid IL2Rg-\/- mouse model. Mol Med Rep. 2020;22(1):362\u201370. https:\/\/doi.org\/10.3892\/mmr.2020.11090.","journal-title":"Mol Med Rep"},{"key":"445_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110393","volume":"129","author":"J Han","year":"2020","unstructured":"Han J, Gu X, Li Y, Wu Q. Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect. Biomed Pharmacother. 2020;129:110393. https:\/\/doi.org\/10.1016\/j.biopha.2020.110393.","journal-title":"Biomed Pharmacother"},{"issue":"18","key":"445_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71243","volume":"14","author":"X Huang","year":"2025","unstructured":"Huang X, Wang X, He Z, Huang Y, Hu B, Chen W, et\u00a0al. Mechanisms, clinical trials, and new treatments for BCG-unresponsive in nonmuscle invasive bladder cancer. Cancer Med. 2025;14(18):e71243. https:\/\/doi.org\/10.1002\/cam4.71243.","journal-title":"Cancer Med"},{"issue":"7","key":"445_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16071356","volume":"16","author":"M Maas","year":"2024","unstructured":"Maas M, Hilsendecker A, Pertoll A, St\u00fchler V, Walz S, Rausch S, et\u00a0al. PD-L1 expression in high-risk non-muscle-invasive bladder cancer is influenced by intravesical Bacillus Calmette-Gu\u00e9rin (BCG) therapy. Cancers. 2024;16(7):1356. https:\/\/doi.org\/10.3390\/cancers16071356.","journal-title":"Cancers"},{"issue":"1","key":"445_CR28","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12943-023-01897-6","volume":"22","author":"K Komura","year":"2023","unstructured":"Komura K, Hirosuna K, Tokushige S, Tsujino T, Nishimura K, Ishida M, et\u00a0al. The impact of FGFR3 alterations on the tumor microenvironment and the efficacy of immune checkpoint inhibitors in bladder cancer. Mol Cancer. 2023;22(1):185. https:\/\/doi.org\/10.1186\/s12943-023-01897-6.","journal-title":"Mol Cancer"},{"issue":"10","key":"445_CR29","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1158\/2326-6066.CIR-23-1114","volume":"12","author":"P Yolmo","year":"2024","unstructured":"Yolmo P, Rahimi S, Chenard S, Conseil G, Jenkins D, Sachdeva K, et\u00a0al. Atypical B cells promote cancer progression and poor response to Bacillus Calmette\u2013Gu\u00e9rin in non-muscle invasive bladder cancer. Cancer Immunol Res. 2024;12(10):1320\u201339. https:\/\/doi.org\/10.1158\/2326-6066.CIR-23-1114.","journal-title":"Cancer Immunol Res"},{"issue":"6 Suppl 4","key":"445_CR30","doi-asserted-by":"publisher","first-page":"S199","DOI":"10.5489\/cuaj.1196","volume":"3","author":"AR Zlotta","year":"2009","unstructured":"Zlotta AR, Fleshner NE, Jewett MA. The management of BCG failure in non-muscle-invasive bladder cancer: an update. Can Urol Assoc J. 2009;3(6 Suppl 4):S199\u2013205. https:\/\/doi.org\/10.5489\/cuaj.1196.","journal-title":"Can Urol Assoc J"},{"issue":"3","key":"445_CR31","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrurol.2014.15","volume":"11","author":"G Redelman-Sidi","year":"2014","unstructured":"Redelman-Sidi G, Glickman MS, Bochner BH. The mechanism of action of BCG therapy for bladder cancer\u2014A current perspective. Nat Rev Urol. 2014;11(3):153\u201362. https:\/\/doi.org\/10.1038\/nrurol.2014.15.","journal-title":"Nat Rev Urol"},{"issue":"6","key":"445_CR32","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.86524","volume":"17","author":"KA Shah","year":"2025","unstructured":"Shah KA, Shah SR, Khan WA, Nisar S, Zaidi SF, Asif M, et\u00a0al. Comparison of intravesical Bacillus Calmette\u2013Gu\u00e9rin (BCG) and Mitomycin C for the treatment of non-muscle-invasive bladder cancer. Cureus. 2025;17(6):e86524. https:\/\/doi.org\/10.7759\/cureus.86524.","journal-title":"Cureus"},{"issue":"4","key":"445_CR33","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","volume":"163","author":"DL Lamm","year":"2000","unstructured":"Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, et\u00a0al. Maintenance Bacillus Calmette-Gu\u00e9rin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. J Urol. 2000;163(4):1124\u20139.","journal-title":"J Urol"},{"issue":"5","key":"445_CR34","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.eururo.2017.10.003","volume":"73","author":"AM Kamat","year":"2018","unstructured":"Kamat AM, Li R, O\u2019Donnell MA, Black PC, Roupret M, Catto JW, et\u00a0al. Predicting response to intravesical Bacillus Calmette-Gu\u00e9rin immunotherapy: are we there yet? A systematic review. Eur Urol. 2018;73(5):738\u201348. https:\/\/doi.org\/10.1016\/j.eururo.2017.10.003.","journal-title":"Eur Urol"},{"issue":"3","key":"445_CR35","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.eururo.2020.02.012","volume":"78","author":"R Li","year":"2020","unstructured":"Li R, Sundi D, Zhang J, Kim Y, Sylvester RJ, Spiess PE, et\u00a0al. Systematic review of the therapeutic efficacy of bladder-preserving treatments for non-muscle-invasive bladder cancer following intravesical Bacillus Calmette\u2013Gu\u00e9rin. Eur Urol. 2020;78(3):387\u201399. https:\/\/doi.org\/10.1016\/j.eururo.2020.02.012.","journal-title":"Eur Urol"},{"key":"445_CR36","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/181987","volume":"2012","author":"EJ Askeland","year":"2012","unstructured":"Askeland EJ, Newton MR, O\u2019Donnell MA, Luo Y. Bladder cancer immunotherapy: BCG and beyond. Adv Urol. 2012;2012:181987. https:\/\/doi.org\/10.1155\/2012\/181987.","journal-title":"Adv Urol"},{"issue":"2","key":"445_CR37","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3233\/BLC-150015","volume":"1","author":"RL Steinberg","year":"2015","unstructured":"Steinberg RL, Thomas LJ, O\u2019Donnell MA. Bacillus Calmette-Gu\u00e9rin (BCG) treatment failures in non-muscle invasive bladder cancer: what truly constitutes unresponsive disease. Bladder cancer (Amsterdam, Netherlands). 2015;1(2):105\u201316. https:\/\/doi.org\/10.3233\/BLC-150015.","journal-title":"Bladder cancer (Amsterdam, Netherlands)"},{"issue":"7528","key":"445_CR38","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/nature13904","volume":"515","author":"T Powles","year":"2014","unstructured":"Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et\u00a0al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515(7528):558\u201362. https:\/\/doi.org\/10.1038\/nature13904.","journal-title":"Nature"},{"issue":"11","key":"445_CR39","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, et\u00a0al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015\u201326. https:\/\/doi.org\/10.1056\/NEJMoa1613683.","journal-title":"N Engl J Med"},{"issue":"16","key":"445_CR40","doi-asserted-by":"publisher","first-page":"20468","DOI":"10.18632\/aging.203429","volume":"13","author":"F Li","year":"2021","unstructured":"Li F, Wang Y, Xie K, Fang Y, Du Y, Hou L, et\u00a0al. The efficacy and safety of PD-1\/PD-L1 immune checkpoint inhibitors in treating advanced urothelial cancer: a meta-analysis of clinical trials. Aging Albany NY. 2021;13(16):20468\u201380. https:\/\/doi.org\/10.18632\/aging.203429.","journal-title":"Aging Albany NY"},{"issue":"4","key":"445_CR41","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.eururo.2017.03.047","volume":"72","author":"T Powles","year":"2017","unstructured":"Powles T, Smith K, Stenzl A, Bedke J. Immune checkpoint inhibition in metastatic urothelial cancer. Eur Urol. 2017;72(4):477\u201381. https:\/\/doi.org\/10.1016\/j.eururo.2017.03.047.","journal-title":"Eur Urol"},{"issue":"7","key":"445_CR42","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","volume":"22","author":"AV Balar","year":"2021","unstructured":"Balar AV, Kamat AM, Kulkarni GS, Uchio EM, Boormans JL, Roumigui\u00e9 M, et\u00a0al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol. 2021;22(7):919\u201330. https:\/\/doi.org\/10.1016\/S1470-2045(21)00147-9.","journal-title":"Lancet Oncol"},{"key":"445_CR43","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/978-3-030-59038-3_17","volume":"1296","author":"K Hatogai","year":"2020","unstructured":"Hatogai K, Sweis RF. The tumor microenvironment of bladder cancer. Adv Exp Med Biol. 2020;1296:275\u201390. https:\/\/doi.org\/10.1007\/978-3-030-59038-3_17.","journal-title":"Adv Exp Med Biol"},{"issue":"3","key":"445_CR44","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3233\/BLC-200277","volume":"6","author":"C Andolfi","year":"2020","unstructured":"Andolfi C, Bloodworth JC, Papachristos A, Sweis RF. The urinary microbiome and bladder cancer: susceptibility and immune responsiveness. Bladder Cancer. 2020;6(3):225\u201335. https:\/\/doi.org\/10.3233\/BLC-200277.","journal-title":"Bladder Cancer"},{"key":"445_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1685237","volume":"16","author":"L Lu","year":"2025","unstructured":"Lu L, Wang F, Wang Z, Guo S, Jiang M, Ma Z. Immune snapshots along the inflammation-to-cancer road in bladder urothelium. Front Immunol. 2025;16:1685237. https:\/\/doi.org\/10.3389\/fimmu.2025.1685237.","journal-title":"Front Immunol"},{"issue":"1","key":"445_CR46","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00194-23","volume":"38","author":"GD Liatsos","year":"2025","unstructured":"Liatsos GD, Mariolis I, Hadziyannis E, Bamias A, Vassilopoulos D. Review of BCG immunotherapy for bladder cancer. Clin Microbiol Rev. 2025;38(1):e0019423. https:\/\/doi.org\/10.1128\/cmr.00194-23.","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"445_CR47","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.eururo.2025.02.010","volume":"88","author":"S Ghodoussipour","year":"2025","unstructured":"Ghodoussipour S, Bivalacqua T, Bryan RT, Li R, Mir MC, Palou J, et\u00a0al. A systematic review of novel intravesical approaches for the treatment of patients with non-muscle-invasive bladder cancer. Eur Urol. 2025;88(1):33\u201355. https:\/\/doi.org\/10.1016\/j.eururo.2025.02.010.","journal-title":"Eur Urol"},{"key":"445_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1591379","volume":"16","author":"Y Wang","year":"2025","unstructured":"Wang Y, He M, Li J, Li L. Immunotherapeutic strategies for invasive bladder cancer: a comprehensive review. Front Immunol. 2025;16:1591379. https:\/\/doi.org\/10.3389\/fimmu.2025.1591379.","journal-title":"Front Immunol"},{"issue":"12","key":"445_CR49","doi-asserted-by":"publisher","first-page":"693.e9","DOI":"10.1016\/j.urolonc.2025.07.005","volume":"43","author":"F Del Giudice","year":"2025","unstructured":"Del Giudice F, Santarelli V, \u0141aszkiewicz J, Li S, Krajewski W, Nowak \u0141, et\u00a0al. The influence of immunocompromised status on recurrence and progression free survival among nonmuscle invasive bladder cancers (NMIBCs) undergoing transurethral resection of bladder tumor (TURBT) and adjuvant intravesical Bacillus Calmette Guerin (BCG): analysis of USA insurance claim data. Urol Oncol. 2025;43(12):693.e9-693.e18. https:\/\/doi.org\/10.1016\/j.urolonc.2025.07.005.","journal-title":"Urol Oncol"},{"key":"445_CR50","doi-asserted-by":"publisher","DOI":"10.1101\/2024.09.02.610816","author":"D Ranti","year":"2025","unstructured":"Ranti D, Yu H, Salom\u00e9 B, Bang S, Duquesne I, Wang YA, et\u00a0al. HLA-E and NKG2A mediate resistance to BCG immunotherapy in non-muscle-invasive bladder cancer. Biorxiv Preprint Serv Biol. 2025. https:\/\/doi.org\/10.1101\/2024.09.02.610816.","journal-title":"Biorxiv Preprint Serv Biol"},{"key":"445_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2025.155997","volume":"270","author":"MZT Lima","year":"2025","unstructured":"Lima MZT, Bastos DA, Mattedi RL, Dzik C, Jardim DLF, Coelho R, et\u00a0al. Infiltrating natural killer cells influence the efficacy of BCG immunotherapy in non-muscle-invasive bladder cancer. Pathol Res Pract. 2025;270:155997. https:\/\/doi.org\/10.1016\/j.prp.2025.155997.","journal-title":"Pathol Res Pract"},{"key":"445_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.tice.2025.103137","volume":"98","author":"JCC Alonso","year":"2026","unstructured":"Alonso JCC, Gon\u00e7alves JM, de Arruda Camargo GC, de Oliveira G, da Silva Santos A, Cintra AA, et\u00a0al. Dual molecular axis of resistance and immunoresponsiveness to BCG in pT1 non-muscle invasive bladder cancer: insights from HER-2, SERBP1, HABP4, and IFN-\u03b3 profiling. Tissue Cell. 2026;98:103137. https:\/\/doi.org\/10.1016\/j.tice.2025.103137.","journal-title":"Tissue Cell"},{"issue":"7","key":"445_CR53","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1158\/0008-5472.CAN-24-1022","volume":"85","author":"MG Prabagar","year":"2025","unstructured":"Prabagar MG, McQueney M, Bommireddy V, Siegel R, Schieven GL, Lu K, et\u00a0al. STING agonist VB-85247 induces durable antitumor immune responses by intravesical administration in a non-muscle-invasive bladder cancer. Cancer Res. 2025;85(7):1287\u201396. https:\/\/doi.org\/10.1158\/0008-5472.CAN-24-1022.","journal-title":"Cancer Res"},{"key":"445_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2025.09.4138","author":"K Meghani","year":"2025","unstructured":"Meghani K, Yu Y, Frydenlund N, Li EZ, Choy B, Abdulkadir SA, et\u00a0al. Genomic and transcriptomic profiling of high-risk bladder cancer reveals diverse molecular and microenvironment ecosystems. Eur Urol. 2025. https:\/\/doi.org\/10.1016\/j.eururo.2025.09.4138.","journal-title":"Eur Urol"},{"issue":"8","key":"445_CR55","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.56434\/j.arch.esp.urol.20257808.133","volume":"78","author":"H K\u00f6seo\u011flu","year":"2025","unstructured":"K\u00f6seo\u011flu H, Yal\u00e7in B, Ero\u011flu T, Y\u00fcceta\u015f U, Mungan U. Qualitative interferon-\u03b3 release assay for predicting response to BCG instillations in bladder cancer. Arch Esp Urol. 2025;78(8):1015\u201321. https:\/\/doi.org\/10.56434\/j.arch.esp.urol.20257808.133.","journal-title":"Arch Esp Urol"},{"issue":"4","key":"445_CR56","doi-asserted-by":"publisher","first-page":"271","DOI":"10.22034\/iji.2024.103549.2846","volume":"21","author":"A Ariafar","year":"2024","unstructured":"Ariafar A, Mansourabadi Z, Alipoor H, Faghih Z. Gamma-delta T cells in bladder cancer draining lymph nodes. Iran J Immunol IJI. 2024;21(4):271\u20138. https:\/\/doi.org\/10.22034\/iji.2024.103549.2846.","journal-title":"Iran J Immunol IJI"},{"issue":"6","key":"445_CR57","doi-asserted-by":"publisher","first-page":"391.e1","DOI":"10.1016\/j.urolonc.2025.01.015","volume":"43","author":"T Gerald","year":"2025","unstructured":"Gerald T, Woldu SL, Halstuch D, Ber Y, Lifshitz K, Cook G, et\u00a0al. Impact of baseline PD-L1 status in BCG naive nonmuscle invasive bladder cancer on outcomes and changes after BCG exposure. Urol Oncol. 2025;43(6):391.e1-391.e10. https:\/\/doi.org\/10.1016\/j.urolonc.2025.01.015.","journal-title":"Urol Oncol"},{"issue":"1","key":"445_CR58","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-024-05392-5","volume":"43","author":"FC de Jong","year":"2025","unstructured":"de Jong FC, Kvikstad V, Hoedemaeker RF, van der Made ACJ, van der Bosch TP, van Casteren NJ, et\u00a0al. PD-L1 expression in high-risk non-muscle invasive bladder cancer is not a biomarker of response to BCG. World J Urol. 2025;43(1):57. https:\/\/doi.org\/10.1007\/s00345-024-05392-5.","journal-title":"World J Urol"},{"issue":"6","key":"445_CR59","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1097\/MOU.0000000000001334","volume":"35","author":"K Oualla","year":"2025","unstructured":"Oualla K, Alem M, Teoh J. Systemic immunotherapy for BCG unresponsive nonmuscle-invasive bladder cancer. Curr Opin Urol. 2025;35(6):636\u201344. https:\/\/doi.org\/10.1097\/MOU.0000000000001334.","journal-title":"Curr Opin Urol"},{"issue":"7528","key":"445_CR60","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et\u00a0al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568\u201371. https:\/\/doi.org\/10.1038\/nature13954.","journal-title":"Nature"},{"issue":"6","key":"445_CR61","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/s43018-025-00986-3","volume":"6","author":"K Aliazis","year":"2025","unstructured":"Aliazis K, Christofides A, Shah R, Yeo YY, Jiang S, Charest A, et\u00a0al. The tumor microenvironment\u2019s role in the response to immune checkpoint blockade. Nat Cancer. 2025;6(6):924\u201337. https:\/\/doi.org\/10.1038\/s43018-025-00986-3.","journal-title":"Nat Cancer"},{"issue":"3","key":"445_CR62","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/exd.14716","volume":"32","author":"S Kawashima","year":"2023","unstructured":"Kawashima S, Togashi Y. Resistance to immune checkpoint inhibitors and the tumor microenvironment. Exp Dermatol. 2023;32(3):240\u20139. https:\/\/doi.org\/10.1111\/exd.14716.","journal-title":"Exp Dermatol"},{"issue":"7637","key":"445_CR63","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321\u201330. https:\/\/doi.org\/10.1038\/nature21349.","journal-title":"Nature"},{"issue":"200","key":"445_CR64","doi-asserted-by":"publisher","first-page":"200ra116","DOI":"10.1126\/scitranslmed.3006504","volume":"5","author":"S Spranger","year":"2013","unstructured":"Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, et\u00a0al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 2013;5(200):200ra116. https:\/\/doi.org\/10.1126\/scitranslmed.3006504.","journal-title":"Sci Transl Med"},{"issue":"3","key":"445_CR65","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","volume":"18","author":"J Galon","year":"2019","unstructured":"Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18(3):197\u2013218. https:\/\/doi.org\/10.1038\/s41573-018-0007-y.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"445_CR66","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et\u00a0al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541\u201350. https:\/\/doi.org\/10.1038\/s41591-018-0014-x.","journal-title":"Nat Med"},{"issue":"9","key":"445_CR67","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, et\u00a0al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375(9):819\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1604958.","journal-title":"N Engl J Med"},{"issue":"4","key":"445_CR68","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707\u201323. https:\/\/doi.org\/10.1016\/j.cell.2017.01.017.","journal-title":"Cell"},{"key":"445_CR69","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3389\/fimmu.2017.00407","volume":"8","author":"JI Moliva","year":"2017","unstructured":"Moliva JI, Turner J, Torrelles JB. Immune responses to Bacillus Calmette\u2013Gu\u00e9rin vaccination: why do they fail to protect against Mycobacterium tuberculosis? Front Immunol. 2017;8:407. https:\/\/doi.org\/10.3389\/fimmu.2017.00407.","journal-title":"Front Immunol"},{"issue":"35","key":"445_CR70","doi-asserted-by":"publisher","first-page":"5437","DOI":"10.1200\/JCO.23.00307","volume":"41","author":"AM Kamat","year":"2023","unstructured":"Kamat AM, Apolo AB, Babjuk M, Bivalacqua TJ, Black PC, Buckley R, et\u00a0al. Definitions, end points, and clinical trial designs for bladder cancer: recommendations from the society for immunotherapy of cancer and the international bladder cancer group. J Clin Oncol. 2023;41(35):5437\u201347. https:\/\/doi.org\/10.1200\/JCO.23.00307.","journal-title":"J Clin Oncol"},{"issue":"2","key":"445_CR71","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s40487-025-00334-6","volume":"13","author":"BE Szabados","year":"2025","unstructured":"Szabados BE, Guerrero-Ramos F, Grande E, Grivas P, Gr\u00fcnwald V, Miguel MC, et\u00a0al. On the horizon: a global multidisciplinary perspective on delivering emerging therapies for patients with BCG-na\u00efve high-risk NMIBC. Oncol Therapy. 2025;13(2):275\u201391. https:\/\/doi.org\/10.1007\/s40487-025-00334-6.","journal-title":"Oncol Therapy"},{"issue":"5","key":"445_CR72","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.euo.2025.03.007","volume":"8","author":"M Longoni","year":"2025","unstructured":"Longoni M, Scilipoti P, Soria F, Pradere B, Krajewski W, D\u2019Andrea D, et\u00a0al. Oncological outcomes in bacillus Calmette\u2013Gu\u00e9rin-na\u00efve High-risk non-muscle-invasive bladder cancer patients: a systematic review on current treatment strategies and future perspectives. Eur Urol Oncol. 2025;8(5):1375\u201392. https:\/\/doi.org\/10.1016\/j.euo.2025.03.007.","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"445_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-025-02489-7","volume":"11","author":"A Turdo","year":"2025","unstructured":"Turdo A, Tulone G, Di Bella S, Porcelli G, D\u2019Accardo C, Gaggianesi M, et\u00a0al. Heightened IDO1 levels predict Bacillus Calmette\u2013Gu\u00e8rin failure in high-risk non-muscle-invasive bladder cancer patients. Cell Death Discov. 2025;11(1):203. https:\/\/doi.org\/10.1038\/s41420-025-02489-7.","journal-title":"Cell Death Discov"},{"issue":"1","key":"445_CR74","doi-asserted-by":"publisher","first-page":"13","DOI":"10.23736\/S2724-6051.24.05910-X","volume":"77","author":"A Artiles Medina","year":"2025","unstructured":"Artiles Medina A, Subiela JD, Tagalos Mu\u00f1oz A, Tato D\u00edez M, M\u00ednguez Ojeda C, L\u00f3pez Curtis D, et\u00a0al. Clinical outcomes of BCG infections in patients undergoing intravesical immunotherapy for non-muscle-invasive bladder cancer: a systematic review and meta-analysis. Minerva Urol Nephrol. 2025;77(1):13\u201324. https:\/\/doi.org\/10.23736\/S2724-6051.24.05910-X.","journal-title":"Minerva Urol Nephrol"},{"issue":"2","key":"445_CR75","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/bju.16509","volume":"135","author":"JI Taylor","year":"2025","unstructured":"Taylor JI, Kamat AM, O\u2019Donnell MA, Annapureddy D, Howard J, Tan WS, et\u00a0al. Long-term outcomes of bladder-sparing therapy vs radical cystectomy in BCG-unresponsive non-muscle-invasive bladder cancer. BJU Int. 2025;135(2):260\u20138. https:\/\/doi.org\/10.1111\/bju.16509.","journal-title":"BJU Int"},{"issue":"4","key":"445_CR76","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.euo.2025.06.003","volume":"8","author":"PE Gabriel","year":"2025","unstructured":"Gabriel PE, Roumigui\u00e9 M, Marcq G, Allory Y, Audenet F, Bajeot AS, et\u00a0al. The evolving landscape of systemic immunotherapy for bacillus Calmette-Gu\u00e9rin-na\u00efve High-risk non-muscle-invasive bladder cancer: at the edge of a tsunami? Eur Urol Oncol. 2025;8(4):1174\u201381. https:\/\/doi.org\/10.1016\/j.euo.2025.06.003.","journal-title":"Eur Urol Oncol"},{"key":"445_CR77","unstructured":"Bristol-Myers Squibb. A phase 3, randomized, double-blind trial of nivolumab in combination with intravesical BCG versus standard of care BCG alone in participants with high-risk non-muscle invasive bladder cancer that is persistent or recurrent after treatment with BCG. ClinicalTrials.gov. 2023. Retrieved September 7, 2023, from https:\/\/clinicaltrials.gov\/study\/NCT04149574."},{"issue":"10516","key":"445_CR78","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1016\/S0140-6736(25)01897-5","volume":"406","author":"M De Santis","year":"2025","unstructured":"De Santis M, Palou Redorta J, Nishiyama H, Krawczy\u0144ski M, Seyitkuliev A, Novikov A, et\u00a0al. Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial. Lancet. 2025;406(10516):2221\u201334. https:\/\/doi.org\/10.1016\/S0140-6736(25)01897-5.","journal-title":"Lancet"},{"issue":"6","key":"445_CR79","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.eururo.2023.01.017","volume":"83","author":"NM Hahn","year":"2023","unstructured":"Hahn NM, O\u2019Donnell MA, Efstathiou JA, Zahurak M, Rosner GL, Smith J, et\u00a0al. A phase 1 trial of Durvalumab in combination with Bacillus Calmette\u2013Guerin (BCG) or external beam radiation therapy in patients with BCG-unresponsive non-muscle-invasive bladder cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER study. Eur Urol. 2023;83(6):486\u201394. https:\/\/doi.org\/10.1016\/j.eururo.2023.01.017.","journal-title":"Eur Urol"},{"key":"445_CR80","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1200\/JCO.2023.41.6_suppl.495","volume":"41","author":"K Chamie","year":"2023","unstructured":"Chamie K, et\u00a0al. Quality of life in QUILT 3.032 study: Patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) receiving IL-15R\u03b1Fc superagonist N-803 plus BCG. J Clin Oncol. 2023;41:495\u2013495. https:\/\/doi.org\/10.1200\/JCO.2023.41.6_suppl.495.","journal-title":"J Clin Oncol"},{"key":"445_CR81","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2025.2587295","author":"KG Keane","year":"2025","unstructured":"Keane KG, Redfern A, Lim J, Hayne D. The role of immune checkpoint inhibitors in the management of NMIBC: a scoping review of current status and future direction. Expert Rev Anticancer Ther. 2025. https:\/\/doi.org\/10.1080\/14737140.2025.2587295. (Advance online publication.).","journal-title":"Expert Rev Anticancer Ther"},{"issue":"11","key":"445_CR82","doi-asserted-by":"publisher","first-page":"490.e13","DOI":"10.1016\/j.urolonc.2022.05.016","volume":"40","author":"M Ferro","year":"2022","unstructured":"Ferro M, Barone B, Crocetto F, Lucarelli G, Busetto GM, Del Giudice F, et\u00a0al. Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancer. Urol Oncol Semin Orig Investig. 2022;40(11):490.e13-490.e20. https:\/\/doi.org\/10.1016\/j.urolonc.2022.05.016.","journal-title":"Urol Oncol Semin Orig Investig"},{"issue":"6","key":"445_CR83","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/S1470-2045(24)00178-5","volume":"25","author":"A Necchi","year":"2024","unstructured":"Necchi A, Roumigui\u00e9 M, Kamat AM, et\u00a0al. Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2024;25(6):720\u201330. https:\/\/doi.org\/10.1016\/S1470-2045(24)00178-5.","journal-title":"Lancet Oncol"},{"key":"445_CR84","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","volume":"22","author":"A Balar","year":"2021","unstructured":"Balar A, Kamat A, Kulkarni G, et\u00a0al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol. 2021;22:919\u201330.","journal-title":"Lancet Oncol"},{"issue":"2","key":"445_CR85","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17020160","volume":"17","author":"J Lahoud","year":"2025","unstructured":"Lahoud J, Okullo A, Rutherford C, Smith DP, Costa DSJ, Tait MA, et\u00a0al. Symptoms and side effects of Bacille Calmette-Guerin therapy for non-muscle invasive bladder cancer as reported by patients: a systematic review. Cancers Basel. 2025;17(2):160. https:\/\/doi.org\/10.3390\/cancers17020160.","journal-title":"Cancers Basel"},{"issue":"10","key":"445_CR86","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.21037\/tau-2025-483","volume":"14","author":"A Albakr","year":"2025","unstructured":"Albakr A, Narayan VM, Tyson M, Shoskes D, Vasavada S. Pharmacotherapy for bladder spasm and irritative lower urinary tract symptoms associated with intravesical therapy for bladder cancer: a review of available evidence. Transl Androl Urol. 2025;14(10):3402\u201312. https:\/\/doi.org\/10.21037\/tau-2025-483.","journal-title":"Transl Androl Urol"},{"issue":"7","key":"445_CR87","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1007\/s11255-025-04375-8","volume":"57","author":"M Gubbiotti","year":"2025","unstructured":"Gubbiotti M, Rubilotta E, Bacchiani M, Cocci A, Rosadi S, Serni S, et\u00a0al. Intravesical administration of highly concentrated hyaluronic acid and chondroitin sulfate as add-on therapy for chemical cystitis induced by Bacillus Calmette\u2013Gu\u00e9rin (BCG) immunotherapy. Int Urol Nephrol. 2025;57(7):2033\u20139. https:\/\/doi.org\/10.1007\/s11255-025-04375-8.","journal-title":"Int Urol Nephrol"},{"issue":"12","key":"445_CR88","doi-asserted-by":"publisher","first-page":"695.e1","DOI":"10.1016\/j.urolonc.2025.08.028","volume":"43","author":"K Obaid","year":"2025","unstructured":"Obaid K, Akp\u0131nar \u00c7, Karaburun MC, \u0130bi\u015f MA, G\u00f6\u011f\u00fc\u015f \u00c7, T\u00fcrk\u00f6lmez K, et\u00a0al. A randomized prospective trial comparing Bacillus Calmette-Gu\u00e9rin (BCG) RIVM and Russian strains in non-muscle invasive bladder cancer: efficacy and side effects. Urol Oncol. 2025;43(12):695.e1-695.e9. https:\/\/doi.org\/10.1016\/j.urolonc.2025.08.028.","journal-title":"Urol Oncol"},{"issue":"1","key":"445_CR89","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.radcr.2025.09.016","volume":"21","author":"B Kova\u010dic","year":"2025","unstructured":"Kova\u010dic B, Ryb\u00e1r \u013d, Hesko P, Kraj\u010dovi\u010d T, Koll\u00e1rik B, Kub\u00edkov\u00e1 E. Granulomatous prostatitis following BCG therapy presenting as a PI-RADS 5 lesion on MRI in the transitional zone: a case report. Radiol Case Rep. 2025;21(1):118\u201321. https:\/\/doi.org\/10.1016\/j.radcr.2025.09.016.","journal-title":"Radiol Case Rep"},{"key":"445_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.eucr.2025.103020","volume":"60","author":"R Yu","year":"2025","unstructured":"Yu R, Qin QJ, Haines GK, Oh WK, Lewis S. Intravesical BCG therapy-induced granulomatous prostatitis in a patient with non-muscle invasive bladder cancer and prostate adenocarcinoma. Urology Case Rep. 2025;60:103020. https:\/\/doi.org\/10.1016\/j.eucr.2025.103020.","journal-title":"Urology Case Rep"},{"issue":"2","key":"445_CR91","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s12328-024-02086-8","volume":"18","author":"Y Hotta","year":"2025","unstructured":"Hotta Y, Yoshioka N, Sakamoto A, Inagaki M, Ito R, Shiraki K, et\u00a0al. Late-onset disseminated BCG infection with hepatosplenomegaly after intravesical BCG immunotherapy in a non-immunocompromised patient. Clin J Gastroenterol. 2025;18(2):337\u201342. https:\/\/doi.org\/10.1007\/s12328-024-02086-8.","journal-title":"Clin J Gastroenterol"},{"key":"445_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2025.102556","volume":"94","author":"Y Sun","year":"2025","unstructured":"Sun Y, Zhang Z, Jia K, Liu H, Zhang F. Autoimmune-related adverse events induced by immune checkpoint inhibitors. Curr Opin Immunol. 2025;94:102556. https:\/\/doi.org\/10.1016\/j.coi.2025.102556.","journal-title":"Curr Opin Immunol"},{"issue":"4","key":"445_CR93","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1002\/ehf2.15281","volume":"12","author":"ML De Perna","year":"2025","unstructured":"De Perna ML, Rigamonti E, Zannoni R, Espeli V, Moschovitis G. Immune checkpoint inhibitors and cardiovascular adverse events. ESC Heart Fail. 2025;12(4):2404\u201316. https:\/\/doi.org\/10.1002\/ehf2.15281.","journal-title":"ESC Heart Fail"},{"issue":"7","key":"445_CR94","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1136\/gutjnl-2024-332125","volume":"74","author":"E De Martin","year":"2025","unstructured":"De Martin E, Fulgenzi CAM, Celsa C, Laurent-Bellue A, Torkpour A, Lombardi P, et\u00a0al. Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse events. Gut. 2025;74(7):1165\u201377. https:\/\/doi.org\/10.1136\/gutjnl-2024-332125.","journal-title":"Gut"},{"issue":"1","key":"445_CR95","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.kint.2024.09.017","volume":"107","author":"SM Herrmann","year":"2025","unstructured":"Herrmann SM, Abudayyeh A, Gupta S, Gudsoorkar P, Klomjit N, Motwani SS, et\u00a0al. Diagnosis and management of immune checkpoint inhibitor-associated nephrotoxicity: a position statement from the American Society of Onco-nephrology. Kidney Int. 2025;107(1):21\u201332. https:\/\/doi.org\/10.1016\/j.kint.2024.09.017.","journal-title":"Kidney Int"},{"issue":"2","key":"445_CR96","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41575-024-01019-7","volume":"22","author":"E Triantafyllou","year":"2025","unstructured":"Triantafyllou E, Gudd CLC, Possamai LA. Immune-mediated liver injury from checkpoint inhibitors: mechanisms, clinical characteristics and management. Nat Rev Gastroenterol Hepatol. 2025;22(2):112\u201326. https:\/\/doi.org\/10.1038\/s41575-024-01019-7.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"445_CR97","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12894-024-01675-6","volume":"25","author":"Z Chen","year":"2025","unstructured":"Chen Z, Chen X, Li D, Jian J, Yao C, Wei X, et\u00a0al. Comparison of treatments for preventing lower urinary tract symptoms after BCG immunotherapy of bladder tumors\u202f: a systematic review and network meta-analysis. BMC Urol. 2025;25(1):19. https:\/\/doi.org\/10.1186\/s12894-024-01675-6.","journal-title":"BMC Urol"},{"key":"445_CR98","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.18870","volume":"13","author":"I Akbulut","year":"2025","unstructured":"Akbulut I, \u00d6demi\u015f \u0130, Atalay S. Analysis of local and systemic side effects of bacillus Calmette\u2013Gu\u00e9rin immunotherapy in bladder cancer: a retrospective study in T\u00fcrkiye. PeerJ. 2025;13:e18870. https:\/\/doi.org\/10.7717\/peerj.18870.","journal-title":"PeerJ"},{"issue":"9","key":"445_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.acuroe.2025.501834","volume":"49","author":"A Farr\u00e9","year":"2025","unstructured":"Farr\u00e9 A, Huguet J, Basile G, Di\u00e9guez L, Izquierdo P, S\u00e1nchez R, et\u00a0al. Oncological outcomes for patients with European Association of Urology definitions of BCG failure treated with radical cystectomy. Actas Urol\u00f3gicas Espa\u00f1olas (English Edition). 2025;49(9):501834. https:\/\/doi.org\/10.1016\/j.acuroe.2025.501834.","journal-title":"Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"},{"issue":"6","key":"445_CR100","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/S1470-2045(24)00178-5","volume":"25","author":"A Necchi","year":"2024","unstructured":"Necchi A, Roumigui\u00e9 M, Kamat AM, Shore ND, Boormans JL, Esen AA, et\u00a0al. Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2024;25(6):720\u201330. https:\/\/doi.org\/10.1016\/S1470-2045(24)00178-5.","journal-title":"Lancet Oncol"},{"issue":"1","key":"445_CR101","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","volume":"22","author":"SA Boorjian","year":"2021","unstructured":"Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, et\u00a0al. Intravesical Nadofaragene Firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021;22(1):107\u201317. https:\/\/doi.org\/10.1016\/S1470-2045(20)30540-4.","journal-title":"Lancet Oncol"},{"issue":"31","key":"445_CR102","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1080\/14796694.2024.2363744","volume":"20","author":"K Chamie","year":"2024","unstructured":"Chamie K, Chang SS, Rosser CJ, Kramolowski E, Gonzalgo ML, Sexton WJ, et\u00a0al. N-803 plus BCG treatment for BCG-na\u00efve or -unresponsive non-muscle invasive bladder cancer: a plain language review. Future Oncol. 2024;20(31):2307\u201317. https:\/\/doi.org\/10.1080\/14796694.2024.2363744.","journal-title":"Future Oncol"},{"issue":"1","key":"445_CR103","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06389-5","volume":"15","author":"L Meng","year":"2024","unstructured":"Meng L, Wu H, Wu J, Ding P, He J, Sang M, et\u00a0al. Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks. Cell Death Dis. 2024;15(1):3. https:\/\/doi.org\/10.1038\/s41419-023-06389-5.","journal-title":"Cell Death Dis"},{"issue":"22","key":"445_CR104","doi-asserted-by":"publisher","DOI":"10.3390\/app152212032","volume":"15","author":"R Mazzucchelli","year":"2025","unstructured":"Mazzucchelli R, Cormio A, Zanelli M, Zizzo M, Palicelli A, Galosi AB, et\u00a0al. Tumor-infiltrating immune cells in non-muscle-invasive bladder cancer: prognostic implications, predictive value, and future perspectives. Appl Sci. 2025;15(22):12032. https:\/\/doi.org\/10.3390\/app152212032.","journal-title":"Appl Sci"},{"issue":"1","key":"445_CR105","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2025.15094","volume":"30","author":"MM Adan","year":"2025","unstructured":"Adan MM, Mao X, Ding L, Abdullahi KM, Li G. Efficacy and safety of BCG and immune checkpoint inhibitors in non-muscle invasive bladder cancer: a meta-analysis with exploratory chemotherapy comparisons. Oncol Lett. 2025;30(1):348. https:\/\/doi.org\/10.3892\/ol.2025.15094.","journal-title":"Oncol Lett"},{"issue":"1","key":"445_CR106","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk M, Burger M, Capoun O, Cohen D, Comp\u00e9rat EM, Dominguez Escrig JL, et\u00a0al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol. 2022;81(1):75\u201394. https:\/\/doi.org\/10.1016\/j.eururo.2021.08.010.","journal-title":"Eur Urol"},{"issue":"5","key":"445_CR107","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","volume":"168","author":"RJ Sylvester","year":"2002","unstructured":"Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical Bacillus Calmette\u2013Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168(5):1964\u201370. https:\/\/doi.org\/10.1016\/S0022-5347(05)64273-5.","journal-title":"J Urol"},{"issue":"6","key":"445_CR108","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22062800","volume":"22","author":"FC de Jong","year":"2021","unstructured":"de Jong FC, Rutten VC, Zuiverloon TCM, Theodorescu D. Improving Anti-PD-1\/PD-L1 therapy for localized bladder cancer. Int J Mol Sci. 2021;22(6):2800. https:\/\/doi.org\/10.3390\/ijms22062800.","journal-title":"Int J Mol Sci"}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-026-00445-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-026-00445-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-026-00445-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T10:32:19Z","timestamp":1789381939000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-026-00445-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":108,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["445"],"URL":"https:\/\/doi.org\/10.1007\/s40487-026-00445-8","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"18 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Michele Musone, Biagio Barone, Stefano Chianese, Paolo Conforti, Antonio Madonna, Silvestro Imperatore, Fabrizio Dinacci, Raffaele Balsamo, Giuseppe Lucarelli, Roberto Falabella, Vincenzo Francesco Caputo, Antonio Luigi Pastore, Andrea Fuschi, Matteo Ferro, Lorenzo Romano, Marco Fabiano, Celeste Manfredi, Gian Maria Busetto, Valerio Santarelli, Francesco Del Giudice, and Felice Crocetto have nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}